Will Velphoro’s Convenience Advantage Be Enough In Crowded ESRD Field?
This article was originally published in The Pink Sheet Daily
Executive Summary
With the field going generic and a new brand competitor with additional advantages on the way, Vifor Pharma is counting on lower pill burden to propel hyperphosphatemia drug Velphoro.